Tevogen Bio Holdings has received a "Strong Buy" rating from a single analyst. This recommendation isn't solely based on technical analysis, which typically involves examining price momentum, patterns, and trends from past data. Technical analysis seeks to gauge market sentiment and predict future price movements based on how investors perceive Tevogen Bio's potential. Let's delve into some key elements of Tevogen's technical analysis to better understand this perspective.
Main Points
Tevogen Bio's recent surge to a last price of 3.05, well below its 200-day moving average of 8.58, suggests a potential buying opportunity for those willing to embrace some volatility. However, with a Sortino Ratio of 0.50, investors should be cautious and consider the risk-reward balance before diving in.
Using predictive
technical analysis, we can analyze different prices and returns patterns and
diagnose historical swings to determine the real value of Tevogen Bio Holdings. In general, sophisticated investors focus on analyzing Tevogen Bio stock price patterns and their correlations with different microeconomic environment and drivers. They apply predictive analytics to build Tevogen Bio's daily price indicators and compare them against related drivers such as
momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional
technical analysis and
fundamental analysis, we attempt to find the most accurate representation of
Tevogen Bio's intrinsic value. In addition to deriving basic predictive indicators for Tevogen Bio, many experienced traders also check how macroeconomic factors affect Tevogen Bio price patterns. Please read more on our
technical analysis page or use our predictive modules below to complement your research.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Tevogen Bio. Your research has to be compared to or analyzed against Tevogen Bio's peers to derive any actionable benefits. When done correctly, Tevogen Bio's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Tevogen Bio Holdings.
How is Tevogen allocating its cash?
To perform a cash flow analysis of Tevogen Bio, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Tevogen Bio is receiving and how much cash it distributes out in a given period. The Tevogen Bio cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Closer look at Tevogen Bio Variance
Tevogen Bio Holdings has current Variance of 684.18. Variance is another measure of security risk that shows the amount of dispersion of equity returns around their mean value. Variance is calculated as the average squared deviations from the mean. Evaluating a set of investment alternatives one can use variance to help determine the volatility when purchasing a specific security. Similar to Standard Deviation, the variance is a measure of how far a set of numbers is spread out around its mean.
Variance is also a measure of stock volatility and can help determine the risk an investor might take on when purchasing a specific security. A relatively big variance indicates that the daily prices or returns are far from the mean and a small variance indicates that they are located around the mean.
Variance | = | SUM(RET DEV)2N |
| = | 684.18 |
| SUM | = | Summation notation |
| RET DEV | = | Actual returns deviation over selected period |
| N | = | Number of points for the period |
Let's now compare Tevogen Bio Variance to its closest peers:
| TVGN | 684.18 |
| MCHX | 9.94 |
| GFF | 10.19 |
| AVRTF | 3.18 |
| PPYAU | 1.51 |
Success usually comes to those who are too busy to be looking for it, said Henry David Thoreau, and Tevogen Bio Holdings seems to embody this spirit as it surges amidst a broader market downturn. With insiders holding a significant 96.61% of shares, confidence within the company appears robust, suggesting a strong alignment of interests between management and shareholders. Despite a challenging financial landscape, marked by a net income loss of 67.3K, the stock's technical indicators, such as a low short ratio of 0.07X, hint at limited bearish sentiment. As the biotech firm navigates its post-IPO phase, its potential upside of 32.61% presents an intriguing opportunity for investors willing to embrace some risk for the promise of substantial returns..
Our perspective of the recent Tevogen Bio roll up
Tevogen Bio Holdings has recently drawn investor interest due to a significant mean deviation increase of over 12.6, hinting at a possible change in market sentiment. This suggests the stock is experiencing heightened volatility, which might reflect shifts in the company's fundamentals or how investors view it. For potential investors, this could signal a growth opportunity, but it's essential to delve into the reasons behind this volatility. As of October 26th, Tevogen Bio shows a semi-deviation of 6.79, a coefficient of variation of 622.03, and a risk-adjusted performance of 0.1358.
It's important to explore these technical indicators and their interconnections thoroughly. Always assess the risks and conduct detailed research before making any investment decisions.Tevogen Bio's impressive performance today, despite a generally lackluster market, highlights its potential as a resilient investment opportunity. With a valuation market value of
3.05 and a naive expected forecast value of
3.78, the stock seems to offer a promising upside for investors willing to navigate the biotech sector's inherent volatility. As always, it's crucial to weigh these prospects against your risk tolerance and investment goals, but Tevogen Bio's current trajectory certainly warrants a closer look for those interested in growth opportunities within the biotech space..
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Aina Ster is a Member of Macroaxis Editorial Board. Aina delivers weekly perspective on ongoing market and economic trends, analysis and tips from predictive analysis to forecasting across various financial instruments.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Aina Ster do not own shares of Tevogen Bio Holdings. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com